Satsuma Pharmaceuticals, Inc.

May 27, 2020

Satsuma Pharmaceuticals to To Present at the Jefferies Virtual Healthcare Conference
May 18, 2020

Satsuma Pharmaceuticals Announces Poster Presentations on the American Academy of Neurology 2020 Science Highlights Virtual Platform

Pharmacokinetic comparison of STS101, an intranasal dry powder formulation of dihydroergotamine, with other intranasal, injectable and oral inhaled DHE formulations
May 12, 2020

Satsuma Pharmaceuticals Reports First Quarter 2020 Financial and Business Results

STS101 EMERGE™ Phase 3 efficacy trial remains on track with announcement of topline data expected in second half of 2020
Apr 28, 2020

Satsuma Pharmaceuticals to Host Key Opinion Leader Event: STS101 and the Acute Treatment of Migraine
Mar 10, 2020

Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Results

On track to announce topline data in second half of 2020 from Phase 3 EMERGE™ efficacy trial evaluating STS101 for the acute treatment of migraine

Show per page